Avacta Group (OTCPK:AVCT.F) - Aktienkurs, Nachrichten und Analyse

AVCT.F Aktienübersicht

Avacta Group Plc entwickelt Krebsmedikamente und In-vitro-Diagnostika im Vereinigten Königreich, in Frankreich, Nordamerika, Südkorea, im übrigen Europa und auf internationaler Ebene. Mehr Details

AVCT.F grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 2.1% pro Jahr sinken.

Aktien sind hochgradig illiquide

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Die Aktionäre wurden im vergangenen Jahr verwässert

Avacta Group Plc Wettbewerber

Mersana Therapeutics

NasdaqGS:MRSN

US$247.1m

Voyager Therapeutics

NasdaqGS:VYGR

US$314.1m

ProQR Therapeutics

NasdaqCM:PRQR

US$365.3m

Sutro Biopharma

NasdaqGM:STRO

US$215.2m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Avacta Group
Historische Aktienkurse
Aktueller Aktienkurs	UK£0.65
52-Wochen-Hoch	UK£2.17
52-Wochen-Tief	UK£0.48
Beta	1.18
11 Monat Veränderung	-19.95%
3 Monate Veränderung	-29.45%
1 Jahr Veränderung	-58.71%
33 Jahre Veränderung	-55.62%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-54.88%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	AVCT.F	US Biotechs	US Markt
7D	0%	4.0%	2.2%
1Y	-58.7%	18.3%	32.6%

Rendite im Vergleich zur Industrie: AVCT.F unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 18.3% erzielte.

Rendite vs. Markt: AVCT.F hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 32.6 erzielte.

Preisvolatilität

Is AVCT.F's price volatile compared to industry and market?
AVCT.F volatility
AVCT.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: AVCT.FDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von AVCT.F im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc entwickelt Krebsmedikamente und In-vitro-Diagnostika im Vereinigten Königreich, Frankreich, Nordamerika, Südkorea, im übrigen Europa und international. Das Unternehmen ist in den Segmenten Diagnostika und Therapeutika tätig. Es bietet seine proprietären Affimer- und pre|CISION-Technologieplattformen an, die zur Bereitstellung eines Portfolios differenzierter therapeutischer und diagnostischer Produkte für verschiedene Märkte verwendet werden.

Avacta Group Plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Avacta Group im Vergleich zum Marktanteil des Unternehmens?
AVCT.F grundlegende Statistiken
Marktanteil	US$229.57m
Gewinn(TTM)	-US$32.48m
Umsatz(TTM)	US$28.38m

8.1x

Kurs-Umsatz-Verhältnis

-7.1x

Kurs-Gewinn-Verhältnis

Ist AVCT.F zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
AVCT.F Gewinn- und Verlustrechnung (TTM)
Einnahmen	UK£22.62m
Kosten der Einnahmen	UK£13.10m
Bruttogewinn	UK£9.52m
Sonstige Ausgaben	UK£35.40m
Umsatz	-UK£25.89m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.071
Bruttomarge	42.08%
Nettogewinnspanne	-114.45%
Schulden/Eigenkapital-Verhältnis	49.8%

Wie hat sich AVCT.F auf lange Sicht entwickelt?

Historische Performance und Vergleiche

AVCT.F Aktienübersicht

Risikoanalyse

Avacta Group Plc Wettbewerber

NasdaqGS:MRSN

US$247.1m

NasdaqGS:VYGR

US$314.1m

NasdaqCM:PRQR

US$365.3m

NasdaqGM:STRO

US$215.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA

Avacta Group plc Announces Results of Initial Evaluation of Sars-Cov-2 Lateral Flow Antigen Test with Clinical Samples

Avacta Group plc Enters into Commercial Partnership with Mologic Ltd

Avacta Announces Collaboration Agreement with Bruker

Avacta Group plc Announces License Agreement with Point Biopharma Inc

Avacta Submits Clinical Trial Application for Ava6000 Pro-Doxorubixin

Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology

Avacta Group plc Announces Significant Progress in Development of a Highly Scalable Manufacturing Process for Lateral Flow SARS-CoV-2 Antigen Test

Avacta Group Plc Launches SARS-CoV-2 BAMS Research Test

Aktionärsrenditen

Erträge & Einnahmen